Pharmacokinetics, pharmacodynamics, and tolerability of ACT-077825, a new direct renin inhibitor after multiple-ascending doses in healthy subjects

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 1, 2013, Pages 42-50

  Nicolas, Laurent B ^a   Gutierrez, Marcelo ^a   Binkert, Christoph ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

healthy subjects; pharmacodynamics; pharmacokinetics; renin inhibitor; renin angiotensin aldosterone system

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ACT 077825; ALDOSTERONE; CREATININE; CYTOCHROME P450 3A4; ENALAPRIL; POTASSIUM; RENIN; RENIN INHIBITOR; SODIUM; UNCLASSIFIED DRUG;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NORMAL HUMAN; POTASSIUM BLOOD LEVEL; POTASSIUM RESTRICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SODIUM RESTRICTION; STEADY STATE; URINALYSIS; URINARY EXCRETION;

ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENALAPRIL; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; RENIN; RENIN-ANGIOTENSIN SYSTEM; SWITZERLAND; TOLUENE; YOUNG ADULT;

EID: 84872344365     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318276d444     Document Type: Article

References (24)

1. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13 (8 suppl B):9-20.
2. Maibaum J, Feldman D. Renin inhibitors as novel treatments for cardiovascular disease. Exp Opin Ther Patents. 2003;13:589-603.
3. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol. 2006;1:221-228.
4. Sleight P, Yusuf S. New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens. 2003;21:1599-1608.
5. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin- aldosterone system. Nat Rev Drug Discov. 2002;1:621-636.
6. Ma TK, Kam KK, Yan BP, et al. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160:1273-1292.
7. Azizi M,Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243-256.
8. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;368: 1449-1456.
9. Bing J. Rapid marked increase in plasma renin in rats treated with inhibitors of the renin system. Effects of 1-sar-8-ala-angiotensin II and of a synthetic converting enzyme inhibitor (nonapeptide, SQ 20.881) on normal and adrenalectomized rats. Acta Pathol Microbiol Scand A. 1973;81:376-378.
10. Bezencon O, Bur D, Weller T, et al. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. J Med Chem. 2009;52:3689-3702.
11. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs. 2007;67:1767-1792.
12. Nicolas LB, Gutierrez MM, Binkert C, et al. Entry-into-humans study with a new direct renin inhibitor. Eur J Clin Pharmacol. 2012;68:1257-1266.
13. Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol. 2003;59:713-733.
14. Gough K. Assessment of dose proportionality: reports from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working group. Drug Inf J. 1995;29:1039-1048.
15. Daugherty KK. Aliskiren. Am J Health Syst Pharm. 2008;65:1323-1332.
16. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23: 1296-1310.
17. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1-E8.
18. Morganti A, Lonati C. Aliskiren: the first direct renin inhibitor available for clinical use. J Nephrol. 2011;24:541-549.
19. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126-3133.
20. Nussberger J, Delabays A, De Gasparo M, et al. Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers. Hypertension. 1989;13(6 pt 2):948-953.
21. de Gasparo M, Cumin F, Nussberger J, et al. Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol. 1989;27:587-596.
22. Camenzind E, Nussberger J, Juillerat L, et al. Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans. J Cardiovasc Pharmacol. 1991;18:299-307.
23. Nussberger J, Brunner DB, Waeber B, et al. True versus immunoreactive angiotensin II in human plasma. Hypertension. 1985;7(3 pt 2):I1-I7.
24. Naik GO, Moe GW. Simultaneous separation of angiotensin and endothelin peptide families by high-performance liquid chromatography: application to the specific radioimmunoassay measurement of angiotensin II or endothelin-1 from tissue. J Chromatogr A. 2000;870: 349-361.